A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Purpose: A multi-centre randomized phase II study of single agent nolatrexed dihydrochloride Versus doxorubicin was undertaken in Chinese patients with advanced hepatocellular carcinoma (HCC) to study and compare the clinical efficacy of the two drugs. Methods: Fifty-four patients with clinical or histological diagnosis of HCC were randomized in a 2:1 ratio to receive nolatrexed or doxorubicin. Nolatrexed 725 mg/m(2)/day was given by continuous infusion via a central venous device for 5 days and doxorubicin 60 mg/m(2) was given as a rapid intravenous infusion every 3 weeks. Results: No objective responses were observed in either treatment arm. Two patients in the nolatrexed arm and none in the doxorubicin arm had > 50% decline in serum alpha-fetoprotein. The median survival for the patients in the nolatrexed and doxorubicin arms was 139 days and 104 days, respectively. Moderate toxicities including leukopenia, thrombocytopenia, mucositis and skin rash were observed in both treatment arms. Conclusion: Nolatrexed and doxorubicin are minimally active in the treatment of advanced HCC. Given the small sample size, no difference is observed between the two drugs.
著者Mok TSK, Leung TWT, Lee SD, Chao Y, Chan ATC, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P
期刊名稱Cancer Chemotherapy and Pharmacology
出版年份1999
月份10
日期1
卷號44
期次4
出版社SPRINGER VERLAG
頁次307 - 311
國際標準期刊號0344-5704
電子國際標準期刊號1432-0843
語言英式英語
關鍵詞doxorubicin; hepatocellular carcinoma; nolatrexed; randomized study
Web of Science 學科類別Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2021-18-09 於 00:40